Page 5 - Tom Mikkelsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

National competition returns to recognize top startups in Canada s AgeTech sector

National competition returns to recognize top startups in Canada s AgeTech sector
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.

Bereskin parrAlex mihailidisTom mikkelsenOntario brain institute keyOntario brain instituteCanada technologyNetwork of centres excellenceNetworks of centres excellenceNational impactAgetech innovation weekScientific directorImpact challengeKey sponsorடோம் மைக்கேல்சன்ஆஂடேரியொ மூளை நிறுவனம்கனடா தொழில்நுட்பம்

Roche Canada Artificial Intelligence Centre of Excellence opens digital competition to tackle ALS

Roche Canada Artificial Intelligence Centre of Excellence opens digital competition to tackle ALS
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.

Tom mikkelsenDavid taylorVp researchSociety of canadaRoche canada ai centre of excellenceAi centre of excellence coCanadian institute for advanced researchDigital healthRoche data science coalitionVector instituteFanny sieStrategic healthcare partnerBoard collaboratorRoche canadaScientific directorCanadian institute

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer

at Henry Ford Health System . “Through global collaboration, GBM AGILE is making it possible for some of the world’s foremost experts in glioblastoma research and treatment to collaborate and advance the pace at which scientific and clinical breakthroughs can be achieved.” After opening at Henry Ford Cancer Institute, the two new interventions – VAL-083 from Kintara Therapeutics, Inc. and paxalisib from Kazia Therapeutics Limited– will subsequently open at more than 35 trial sites across the United States, with additional global sites in Canada, Europe and China to follow. VAL-083 is being evaluated in all three glioblastoma patient subtypes: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent.

United statesTom mikkelsenNational cancer instituteGlobal coalition for adaptive researchKintara therapeutics incPrecision medicine programHenry ford cancer instituteNational foundation for cancer researchNational brain tumor societyAsian fund for cancer researchEuropean medicines agencyKazia therapeuticsGlobal coalitionAdaptive researchFord cancer instituteClinical trials office

Henry Ford Health System First in World to Test Treatments for Brain Cancer

DBusiness Magazine Henry Ford Health System First in World to Test Treatments for Brain Cancer Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to activate two treatments for glioblastoma, the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial called GBM AGILE. Henry Ford Cancer Institute is the first on the planet to active two treatments for the deadliest form of brain cancer. // Photo courtesy of Henry Ford Health System Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to activate two treatments for glioblastoma, the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial called GBM AGILE.

Henry fordTom mikkelsenGlobal coalition for adaptive researchNational cancer instituteDrug administrationKazia therapeutics ltdPrecision medicine programHenry ford cancer instituteHenry ford health systemEuropean medicines agencyClinical trials officeHenry ford healthGlobal coalitionAdaptive researchKintara therapeuticsKazia therapeutics

Henry Ford Cancer Institute first-in-world to activate new treatments in GBM AGILE Trial

E-Mail IMAGE: Tom Mikkelsen, M.D., principal investigator for GBM AGILE at Henry Ford Cancer Institute, and medical director of the Precision Medicine Program and Clinical Trials Office at Henry Ford Health System.. view more Credit: Henry Ford Health System DETROIT (Feb. 3, 2021) - Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). Led by Global Coalition for Adaptive Research (GCAR), GBM AGILE tests multiple therapies for patients with newly-diagnosed and recurrent GBM.

United statesTom mikkelsenNational cancer instituteGlobal coalition for adaptive researchKintara therapeutics incPrecision medicine programHenry ford cancer instituteNational foundation for cancer researchNational brain tumor societyAsian fund for cancer researchEuropean medicines agencyFord cancer instituteGlobal coalitionAdaptive researchClinical trials officeHenry ford health